Pravastatin in Polycystic Kidney Disease

Phase 3

Completed

• Conditions: Polycystic Kidney Disease; Renal and Urogenital - Kidney disease

• Registration Number: ACTRN12608000447358
• Lead Sponsor: Clifford Craig Medical Research Trust

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-09-08
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Polycystic kidney disease

Exclusion Criteria

Females of Child bearing potential

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum Creatinine (blood analysis)[every 3 months for 2 years]

Secondary Outcome Measures

Name	Time	Method
Proteinuria measured by 24 hour urine collection[every 3 months for 2 years]